In Reply

Ishak A. Mansi; Ildiko Lingvay; Carlos A. Alvarez

doi:10.1001/jamainternmed.2021.8356

In Reply

Ishak A. Mansi, Ildiko Lingvay, Carlos A. Alvarez

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	460
Number of pages	1
Journal	JAMA Internal Medicine
Volume	182
Issue number	4
DOIs	https://doi.org/10.1001/jamainternmed.2021.8356
State	Published - Apr 2022

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1001/jamainternmed.2021.8356

Cite this

@article{9c5cc0ebcc694e33b2b395a7119b0794,

title = "In Reply",

author = "Mansi, {Ishak A.} and Ildiko Lingvay and Alvarez, {Carlos A.}",

note = "Funding Information: Published Online: February 14, 2022. doi:10.1001/jamainternmed.2021.8310 Conflict of Interest Disclosures: Dr Buetti reported a fellowship grant from the Swiss National Science Foundation (No. P4P4PM19 4449). No other disclosures were reported. 1. Buetti N, Abbas M, Pittet D, et al. Comparison of routine replacement with clinically indicated replacement of peripheral intravenous catheters. JAMA Intern Med. 2021;181(11):1471-1478. doi:10.1001/jamainternmed.2021.5345 2. Tatsuno K, Ikeda M, Wakabayashi Y, Yanagimoto S, Okugawa S, Moriya K. Clinical features of bloodstream infections associated with peripheral versus central venous catheters. Infect Dis Ther. 2019;8(3):343-352. doi:10.1007/ s40121-019-00257-6 3. Webster J, Osborne S, Rickard CM, Marsh N. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2019;1:CD007798. doi:10.1002/14651858.CD007798.pub5 4. Rickard CM, Webster J, Wallis MC, et al. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet. 2012;380(9847):1066-1074. doi:10.1016/S0140-6736 (12)61082-4 5. Buetti N, Ruckly S, Lucet JC, et al. Local signs at insertion site and catheter-related bloodstream infections: an observational post hoc analysis using individual data of four RCTs. Crit Care. 2020;24(1):694. doi:10.1186/ s13054-020-03425-0 Funding Information: Published Online: February 21, 2022. doi:10.1001/jamainternmed.2021.8356 Conflict of Interest Disclosures: Dr Lingvay reported institutional grants from Novo Nordisk, Merck, Pfizer, Mylan, and Sanofi; and consulting fees from Novo Nordisk, Sanofi, Eli Lilly, Janssen, Boehringer Ingelheim, Intercept, Zealand Pharma, Valeritas, Bayer, Intarcia, Mannkind, and Target PharmaSolutions, all outside the submitted work. Dr Alvarez reported a grant from the US National Institutes of Health (No. K08DK101602) during the conduct of the study; and grants from Merck for a pneumonia vaccine study outside the submitted work. No other disclosures were reported. 1. Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med. 2021;181(12):1562-1574. doi:10.1001/ jamainternmed.2021.5714 2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046-e1081. 3. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care. 2021; 44(S1)(suppl 1):S125-S150. doi:10.2337/dc21-S010 4. Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374(n1537): n1537. doi:10.1136/bmj.n1537 5. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274. doi:10.7326/ M16-2607",

year = "2022",

month = apr,

doi = "10.1001/jamainternmed.2021.8356",

language = "English (US)",

volume = "182",

pages = "460",

journal = "JAMA Internal Medicine",

issn = "2168-6106",

publisher = "American Medical Association",

number = "4",

}

TY - JOUR

T1 - In Reply

AU - Mansi, Ishak A.

AU - Lingvay, Ildiko

AU - Alvarez, Carlos A.

N1 - Funding Information: Published Online: February 14, 2022. doi:10.1001/jamainternmed.2021.8310 Conflict of Interest Disclosures: Dr Buetti reported a fellowship grant from the Swiss National Science Foundation (No. P4P4PM19 4449). No other disclosures were reported. 1. Buetti N, Abbas M, Pittet D, et al. Comparison of routine replacement with clinically indicated replacement of peripheral intravenous catheters. JAMA Intern Med. 2021;181(11):1471-1478. doi:10.1001/jamainternmed.2021.5345 2. Tatsuno K, Ikeda M, Wakabayashi Y, Yanagimoto S, Okugawa S, Moriya K. Clinical features of bloodstream infections associated with peripheral versus central venous catheters. Infect Dis Ther. 2019;8(3):343-352. doi:10.1007/ s40121-019-00257-6 3. Webster J, Osborne S, Rickard CM, Marsh N. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2019;1:CD007798. doi:10.1002/14651858.CD007798.pub5 4. Rickard CM, Webster J, Wallis MC, et al. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet. 2012;380(9847):1066-1074. doi:10.1016/S0140-6736 (12)61082-4 5. Buetti N, Ruckly S, Lucet JC, et al. Local signs at insertion site and catheter-related bloodstream infections: an observational post hoc analysis using individual data of four RCTs. Crit Care. 2020;24(1):694. doi:10.1186/ s13054-020-03425-0 Funding Information: Published Online: February 21, 2022. doi:10.1001/jamainternmed.2021.8356 Conflict of Interest Disclosures: Dr Lingvay reported institutional grants from Novo Nordisk, Merck, Pfizer, Mylan, and Sanofi; and consulting fees from Novo Nordisk, Sanofi, Eli Lilly, Janssen, Boehringer Ingelheim, Intercept, Zealand Pharma, Valeritas, Bayer, Intarcia, Mannkind, and Target PharmaSolutions, all outside the submitted work. Dr Alvarez reported a grant from the US National Institutes of Health (No. K08DK101602) during the conduct of the study; and grants from Merck for a pneumonia vaccine study outside the submitted work. No other disclosures were reported. 1. Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern Med. 2021;181(12):1562-1574. doi:10.1001/ jamainternmed.2021.5714 2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046-e1081. 3. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care. 2021; 44(S1)(suppl 1):S125-S150. doi:10.2337/dc21-S010 4. Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374(n1537): n1537. doi:10.1136/bmj.n1537 5. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274. doi:10.7326/ M16-2607

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85124967501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124967501&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2021.8356

DO - 10.1001/jamainternmed.2021.8356

M3 - Letter

C2 - 35188526

AN - SCOPUS:85124967501

SN - 2168-6106

VL - 182

SP - 460

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

IS - 4

ER -

In Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this